Altamira Therapeutics Ltd

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through the following geographical segments: United States, Switzerland, Europe, and Australia. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Earnings data Q3 2024

Earnings data Q4 2024

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through the Switzerland and Australia geographical segments. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

HAMILTON, BERMUDA , Sept. 14, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced further positive and statistically significant efficacy data from the randomized controlled NASAR clinical trial, which evaluated their Bentrio nasal spray in seasonal allergic rhinitis (SAR). Bentrio nasal spray is formulated as a drug-free and preservative-free gel emulsion designed to help protect against airborne allergens such as pollen or house dust mites.

Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis

Altamira Therapeutics Ltd. (NASDAQ:CYTO ) Q2 2023 Earnings Conference Call September 12, 2023 8:00 AM ET Company Participants Thomas Meyer - Founder, Chairman & CEO Covadonga Paneda - Chief Operating Officer Conference Call Participants Operator Good morning, and welcome to the Altamira Therapeutics First Half 2023 Financial Results and Business Update Conference Call.

Altamira Therapeutics Ltd. (CYTO) Q2 2023 Earnings Call Transcript

HAMILTON, BERMUDA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs, today provided a business update and reported its first half 2023 financial results.

Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results

HAMILTON, BERMUDA , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced that it will host its First Half of 2023 Financial Results and Business Update Call on Tuesday, September 12, 2023. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks followed by a Q&A session where they will address questions from investors and analysts.

Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th

HAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its founder, Chairman, and CEO Thomas Meyer will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference, being held virtually and in person on September 11-13, 2023, at Lotte New York Palace Hotel in New York City.

Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

HAMILTON, BERMUDA, July 20, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today that it has entered into an exclusive agreement with Pharma Nordic AS for the marketing and distribution of Bentrio®, a nasal spray for protection against airborne allergens, in Norway and potentially further Scandinavian countries. The collaboration agreement will allow Pharma Nordic to market and commercialize Bentrio in Norway beginning in the first quarter of 2024, and, subject to meeting certain milestones, also in Sweden, Finland, and Denmark later on.

Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in Scandinavia

HAMILTON, BERMUDA, July 17, 2023 (GLOBE NEWSWIRE) -- -Detailed results from house dust mite trial published in Clinical and Translational Allergy -Study demonstrates statistically significant alleviation of nasal symptoms of allergic rhinitis

Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed Journal

HAMILTON, BERMUDA / ACCESSWIRE / July 6, 2023 / Altamira Therapeutics Ltd. ("Company") (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, announced today the pricing of a public offering of 11,111,112 common shares (or pre-funded warrants in lieu thereof) accompanied by common warrants to purchase up to 11,111,112 common shares, at a combined public offering price of $0.45 per share (or pre-funded warrant in lieu thereof) and accompanying common warrant.

Altamira Therapeutics Announces Pricing of $5.0 Million Public Offering

HAMILTON, BERMUDA , July 05, 2023 (GLOBE NEWSWIRE) -- Heqet will test nanoparticles based on Altamira's OligoPhore delivery platform in the regeneration of damaged heart tissue

Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration

HAMILTON, BERMUDA / ACCESSWIRE / June 15, 2023 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that the U.S. Food and Drug Administration ("FDA") has completed its safety review of the Company's Investigational New Drug (IND) application for AM-125 (betahistine nasal spray) in acute vestibular syndrome (AVS).

Altamira Therapeutics Announces IND Clearance by U.S. FDA for AM-125 in Acute Vestibular Syndrome

HAMILTON, BERMUDA / ACCESSWIRE / May 31, 2023 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced the publication of a peer-reviewed article in the International Journal of Molecular Sciences (IJMS) reviewing the challenges in the safe and effective delivery of RNA molecules to target cells beyond the liver.

Altamira Therapeutics Announces Publication of Peer-Reviewed Article on Peptide-Based RNA Delivery for Extrahepatic Targets

Getaround Inc

Minerva Surgical

If you're looking for the best penny stocks to buy today, you should be well-prepared to deal with high volatility. Whether it's the latest debt ceiling crisis, pandemic fear reemerging, today's Fed meeting minutes from May, or speeches by Janet Yellen and Federal Reserve members, there are plenty of headlines to contend with.

Best Penny Stocks Today? 3 Under $1 To Watch Now

Bentrio® meets primary efficacy endpoint in NASAR clinical trial in seasonal allergic rhinitis Clinically relevant and statistically significant improvement in Total Nasal Symptom Score over saline nasal spray control (p = 0.012) Bentrio efficacy and tolerability rated as "good" or "very good" by 63.5% and 73.5% of study participants NASAR concludes Altamira's clinical development program for Bentrio in allergic rhinitis HAMILTON, BERMUDA / ACCESSWIRE / May 24, 2023 / Altamira Therapeutics Ltd. (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced positive and statistically significant top-line results from the randomized controlled NASAR clinical trial evaluating its Bentrio nasal spray in patients with seasonal allergic rhinitis (SAR).

Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic Rhinitis

Altamira Therapeutics Ltd. (NASDAQ:CYTO ) Q4 2022 Earnings Conference Call May 16, 2023 8:00 AM ET Company Participants Thomas Meyer - Founder, Chairman and Chief Executive Officer Covadonga Pañeda - Chief Operating Officer Conference Call Participants Operator Good morning, and welcome to the Altamira Therapeutics 2022 Results Conference Call.

Altamira Therapeutics Ltd. (CYTO) Q4 2022 Earnings Call Transcript

Management will host an investor conference call today, May 16th, at 8 a.m. Eastern Company is advancing OligoPhore™ / SemaPhore™ platform for extrahepatic RNA delivery and efficient endosomal release; expects first research collaborations with biopharmaceutical companies in 2023 Filed IND submission with FDA for AM-125 in acute vestibular syndrome ‘Showcase' RNA development programs AM-401 and AM-411 progressing in KRAS-driven cancers and rheumatoid arthritis, targeting INDs in 2024 Divestiture or partnering of legacy assets remains a key strategic focus Top-line data from full NASAR trial with Bentrio in seasonal allergic rhinitis expected in the second quarter HAMILTON, BERMUDA / ACCESSWIRE / May 16, 2023 / Altamira Therapeutics Ltd.

Altamira Therapeutics Provides Business Update, Reports FY 2022 Financial Results

HAMILTON, BERMUDA / ACCESSWIRE / May 12, 2023 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing and commercializing RNA delivery technology for extrahepatic targets, announced that it will host its Fiscal Year 2022 Financial Results and Business Update Call on Tuesday, May 16, 2023.

Altamira Therapeutics to Host Fiscal Year 2022 Financial Results and Business Update Call on May 16th 2023

Faraday Future Intelligent Electric

SaverOne 2014 Ltd

Use these tips to day trade penny stocks in 2023 The post 3 Tips for Day Trading Penny Stocks in 2023  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Tips for Day Trading Penny Stocks in 2023

Altamira Therapeutics (NASDAQ: CYTO ) stock is taking off on Thursday despite a lack of news from the RNA-based therapeutics company. There are no new press releases from Altamira Therapeutics that explain why the company's shares are rising today.

Why Is Altamira Therapeutics (CYTO) Stock Up 45% Today?

HAMILTON, BERMUDA / ACCESSWIRE / May 1, 2023 / Altamira Therapeutics ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its founder, chairman, and CEO Thomas Meyer will be presenting at the Sidoti Micro-Cap Conference, being held virtually on May 10 - 11, 2023. Event: Sidoti Micro-Cap Virtual Conference Date: Wednesday, May 10th Time: 1:00-1:30 PM in Track 3 Webcast: https://sidoti.zoom.us/webinar/register/WN_BUoSrU7ETIGtYOKZzzSB7g Registration: Link *Please note that Company presentation date and time are subject to change.

Altamira Therapeutics CEO & Chairman to Present at Sidoti Micro-Cap Virtual Conference May 10-11

Creative Medical Technology Holdings

National CineMedia

Use these strategies for making money with penny stocks in 2023 The post 3 Methods for Finding Penny Stocks to Buy and Hold appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Methods for Finding Penny Stocks to Buy and Hold

Detailed results from TRAVERS trial addressing acute vestibular syndrome with AM-125 (intranasal betahistine) published in Otology & Neurotology Study demonstrates proof of concept and shows good tolerability TRAVERS shows time and dose dependent acceleration of vestibular compensation and alleviation of signs and symptoms of vestibular dysfunction Altamira intends to partner or divest AM-125, part of its legacy assets, in a strategic pivot to RNA delivery technology HAMILTON, BERMUDA / ACCESSWIRE / April 12, 2023 / Altamira Therapeutics ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced the publication of the detailed results from its TRAVERS Phase 2 trial with AM-125 (intranasal betahistine) in surgery-induced acute vestibular syndrome (AVS). The peer-reviewed article was published in Otology & Neurotology, one of the leading journals in scientific and clinical inner ear research.

Altamira Therapeutics Announces Publication of Positive Results from Phase 2 Trial with AM-125 in Acute Vestibular Syndrome in Leading Peer Reviewed Journal

Altamira Therapeutics (NASDAQ: CYTO ) stock is taking off on Wednesday after providing an update on its SemaPhore nanoparticle technology. According to a press release from Altamira Therapeutics, SemaPhore has the potential to serve the mRNA applications market.

Why Is Altamira Therapeutics (CYTO) Stock Up 64% Today?

Altamira's peptide-based SemaPhore™ nanoparticle technology confers great stability to mRNA, is non-immunogenic and non-toxic, enabling delivery to extrahepatic targets and efficient endosomal release Continued momentum in mRNA vaccines and therapeutics with over 840 programs under development, according to fresh data from Beacon RNA database by Hanson Wade Limitations of hitherto dominant lipid nanoparticle (LNP) technologies call for alternate mRNA delivery solutions HAMILTON, BERMUDA / ACCESSWIRE / April 11, 2023 / Altamira Therapeutics ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing RNA-based therapeutics that address important unmet medical needs, positions its peptide-based SemaPhore™ nanoparticle technology as a versatile and efficient alternative to the hitherto dominant lipid nanoparticle (LNP) delivery technologies in the fast growing field of mRNA (messenger ribonucleic acid) applications. According to fresh data from the Beacon RNA database by Hanson Wade, the number of mRNA vaccines and therapeutics under development has now grown to more than 840, of which 356 are using some sort of LNP for delivery.

Altamira Therapeutics Positions its Patented SemaPhore mRNA Delivery Platform as Versatile and Efficient Alternative to Lipid Nanoparticles

Nektar Therapeutics

Sirius XM Hlds

Virios Therapeutics

Penny stocks, the stock market game & what traders are watching this week. The post 4 Penny Stocks To Watch If You're Playing The “Stock Market Game” appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Watch If You're Playing The “Stock Market Game”

Published meta-analysis shows statistically significant improvement in dizziness handicap for betahistine treatment over standard of care procedure alone in patients suffering from BPPV Altamira to file IND application for intranasal betahistine (AM-125) with FDA in May 2023, including protocol for Phase 2 clinical trial in BPPV Altamira intends to partner or divest AM-125 as part of its legacy assets in a strategic pivot to its RNA delivery technology platforms HAMILTON, BERMUDA / ACCESSWIRE / April 10, 2023 / Altamira Therapeutics ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today reported highlights from a peer reviewed article showing efficacy of oral betahistine in the treatment of posterior canal benign paroxysmal positional vertigo (BPPV) when administered along with a canal repositioning procedure, the Epley maneuver. The article was published in the journal Medicine[1] and describes the results from a meta-analysis of nine randomized controlled trials with 860 posterior canal BPPV patients, of which 432 were treated with Epley's maneuver plus betahistine, and 428 solely underwent Epley's maneuver.

Altamira Therapeutics Reports Positive Conclusions from Independent Meta-Analysis of Clinical Studies with Betahistine in Treatment of Most Common Cause of Vertigo

News for Altamira Therapeutics Ltd Stock (CYTO)